Replies to post #645948 on NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

This board has hyped NWBO patents for 12 years and the stock is 95% off it's high with a bloated OS.

What a crock of .....!

Everyone knows that the IP NWBO has patented is of extreme importance, when DCVax-L gets approved and Flaskworks Eden will be used to manufacture, automate and scale the vaccines and with a cherry on top of hte patents ... orphan drug designation.

Regarding NWBOs IP from their own annual report latest december 2022.

Intellectual Property and Orphan Drug Designation

We have an integrated strategy for protection of our technology through both patents and other mechanisms, such as Orphan Drug status. As of December 31, 2022, we have 103 issued patents and 64 pending patent applications worldwide, grouped into 9 patent families. Of these, 98 issued patents and 43 pending patent applications directly relate to our DCVax products. In the United States and Europe, some of our patents and applications relate to compositions and the use of products, while other patents and applications relate to other aspects such as manufacturing. For example, in the United States, we have six issued patents and four pending patent applications that relate to the composition and/or use of our DCVax products. We also have other US patents and applications that cover, among other things, a potential method for determining the immunopotency of our dendritic cells produced by our manufacturing processes and an automated system which we believe will help enable the scale-up of production for large numbers of patients on a cost-effective basis. Similarly, in Europe, we have five patents, validated as 59 national patents, issued by and four pending patent applications with the European Patent Office (“EPO”) that cover our DCVax products, and other patents and applications that cover aspects such as manufacturing, a potential method for determining immunopotency of our manufactured products, and the automated system. In Japan, we have seven issued patents and four pending patent applications relating to our DCVax products, as well as manufacturing related patents. Patents have been granted or are pending in other foreign jurisdictions which may be potential future markets for our DCVax products.

During 2022, four new patents were issued to us as part of our worldwide patent portfolio. The European patent was validated as 16 national patents. The newly issued patents cover methods for manufacturing dendritic cells related to our DCVax products, as well as encompassing certain methods of use and compositions that may be potential future markets for related DCVax products and a potential method for determining the immunopotency of dendritic cells produced by our manufacturing processes.

Additionally, with the acquisition of Flaskworks, we gained ownership of a portfolio of patents and patent applications which include those held by Flaskworks as well as patents and patent applications exclusively licensed by Flaskworks from Northeastern University. The portfolio includes a total of thirteen patent families, with issued patents and pending applications worldwide. Collectively these patents and patent applications cover key aspects of the design and function of automated cell culture systems.

During 2020, three new patents were issued to us as part of our worldwide patent portfolio. The newly issued patents cover methods for manufacturing dendritic cells related to our DCVax products, as well as encompassing certain methods of use and compositions that may be potential future markets for related DCVax products.

The expiration dates of the issued US patents involved in our current business range from 2023 to 2036, and pending applications may involve longer time periods. The expiration dates of the issued European patents involved in our current business range from 2023 to 2036, and pending applications may involve longer time periods. For some of the earlier dates, we plan to seek extensions of the patent life, and believe we have reasonable grounds for doing so.

In addition to our patent portfolio, we have obtained Orphan Drug designation for our lead product, DCVax-L for glioma brain cancers. Such designation brings with it a variety of benefits, including potential market exclusivity for seven years in the US and ten years in Europe if our product is the first of its type to reach the market.

This market exclusivity applies regardless of patents (i.e., even if the company that developed it has no patent coverage on the product). In addition, the time period for such market exclusivity does not begin to run until product sales begin. In contrast, the time period of a patent begins when the patent is filed and runs down during the years while the product is going through development and clinical trials.

Asking BARD

Northwest Biotherapeutics currently has 204 issued patents and 59 pending patent applications worldwide. These patents are grouped into 11 patent families. The patents cover a variety of aspects of the company's technology, including the development of dendritic cell vaccines, the manufacturing of dendritic cell vaccines, and the use of dendritic cell vaccines to treat cancer.

Here is a breakdown of the company's patents by status:

Issued patents: 204
Pending patent applications: 59
The company's most valuable patents are those that cover its core technology for developing dendritic cell vaccines. These patents are essential for the company to continue to develop and commercialize its products.

The company also has a number of patents that cover its manufacturing processes for dendritic cell vaccines. These patents are important for ensuring that the company can produce high-quality vaccines that are safe and effective.

Finally, the company has a number of patents that cover the use of dendritic cell vaccines to treat cancer. These patents could be valuable if the company is successful in developing dendritic cell vaccines that are approved for the treatment of cancer.

Overall, Northwest Biotherapeutics has a strong patent portfolio that protects its technology and its products. The company's patents are a valuable asset that could help the company to achieve its goals of developing and commercializing effective cancer treatments.